The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Long-Term Safety of Drug-Coated Devices for Peripheral Revascularisation

DOI: 10.4244/EIJ-D-20-01018

1. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Bolton, MA, 
2. Harvard Medical School, Boston, MA, USA
3. Division of Cardiology, Department of Medicine; Beth Israel Deaconess Medical Center, Boston, MA, USA
4. Medtronic, Minneapolis, MN, USA
5. CPC Clinical Research, Denver, CO, USA
6. Division of Cardiology, Department of Medicine; University of Colorado Anschutz Medical Campus, Denver, CO, USA
Disclaimer:

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention and external reviewers - has been published immediately upon acceptance as it was received in the last round of revision. The content of this article is the responsibility of the authors.

Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.

To read the full content of this article, please log in to download the PDF.

Background: Meta-analyses of randomised trials of paclitaxel-coated peripheral devices found an association with worse long-term survival. We assessed long-term mortality in patients treated with drug-coated devices insured by Medicare Advantage (MA), an alternative to traditional Medicare that represents >30% of the Medicare eligible population.

Methods Patients treated with or without drug-coated devices for femoropopliteal artery revascularisation from 4/2015-12/2017 were studied using Optum’s De-identified Clinformatics® Datamart Database. Mortality was assessed through December 2019 using Kaplan Meier cumulative mortality curves and Cox-proportional hazard models. Inverse probability of treatment weighting was used to adjust for differences between groups.

Results: Of 16,796 patients revascularised, 4,427 (26.4%) were treated with drug-coated devices: 3,600 (81.3%) balloons and 827 (18.7%) stents. The median follow-up was 2.66 years (IQR 2.02–3.52). Treatment with drug-coated devices was associated with similar long-term mortality as nondrug-coated devices (adjusted HR 1.03; 95%CI=0.96-1.10; P=0.39). Results were comparable for patients treated with balloons alone (adjusted HR 1.00; 95%CI=0.92-1.08; P=0.96) or stents (adjusted HR 1.02; 95%CI=0.88-1.18; P=0.78). These findings did not differ based on treatment setting, disease severity, age, sex or comorbidity burden (interaction P>0.05 for all).

Conclusions: In this large cohort, there was no evidence of increased long-term mortality following treatment with drug-coated devices.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Applicability of the ISCHEMIA trial in real-world practice, a new “uncaging” coronary stent, PCI of the left main trifurcation in the EXCEL trial, coronary re-access after TAVI, virtual reality and conscious sedation, renal flow reserve, and more…